This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Some 21 years have elapsed since the first use of artificial radioactive isotopes in cancer diagnosis and treatment. Enthusiasts were initially hopeful that in the near future the profession might witness outstanding examples of selective localization of radioactive materials in neoplastic tissue, making it easy to detect such lesions and possibly providing a means to deliver tumor doses much higher than would be received by the adjacent normal tissues. However, up to the present time, only two radioactive isotopes have been developed to provide important therapeutic applications through relatively selective localization— radiophosphorus (P32) in polycythemia vera and radioiodine (I131) in a small percentage of thyroid carcinomas. This fact has confirmed the belief of many that the greatest contribution of radioactive isotopes in the field of cancer lies in tracer applications. Nevertheless, isotopes do have a place in diagnosis and therapy. The following remarks will attempt to summarize our
Garland LH, Heald JH. RADIOACTIVE ISOTOPES IN THE DIAGNOSIS AND TREATMENT OF CANCER: GUEST EDITORIAL. JAMA. 1957;164(10):1096–1098. doi:https://doi.org/10.1001/jama.1957.02980100052011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: